PharmaCyte Biotech, Inc.
PMCB
$0.72
-$0.03-3.73%
NASDAQ
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 63.97% | 63.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 53.92% | 62.22% | |||
| Operating Income | -53.92% | -62.22% | |||
| Income Before Tax | 110.07% | 11.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 110.07% | 11.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 110.07% | 11.27% | |||
| EBIT | -53.92% | -62.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 86.44% | -0.67% | |||
| Normalized Basic EPS | 91.19% | -30.61% | |||
| EPS Diluted | 86.44% | -0.67% | |||
| Normalized Diluted EPS | 91.19% | -30.61% | |||
| Average Basic Shares Outstanding | 36.30% | 0.00% | |||
| Average Diluted Shares Outstanding | 36.30% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 17.44% | -- | |||